Your search matched 5 results
With a global pandemic, rising inflation, and continued political pressures, drug pricing will undoubtedly remain a big focus in 2022.
While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.
The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.”
What the CMS National Coverage Decision Means for the Life Science Industry
The Biden administration cited health equity as one of its top 5 health priorities in a Health Affairs blog.